Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label C21 monotherapy in idiopathic pulmonary fibrosis (IPF)
2020-000822-24Phase 2Unknown
- Sponsor
- Vicore Pharma
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buloxibutid in idiopathic pulmonary fibrosis (IPF), sponsored by Vicore Pharma. Primary endpoint: Nature and frequency of adverse events. Status: unknown.
02
Drugs
buloxibutid
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2020-000822-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000822-24.